Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.36849/JDD.5363 | DOI Listing |
Lancet
January 2025
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:
Background: Dermatomyositis is a chronic autoimmune disease with distinctive cutaneous eruptions and muscle weakness, and the pathophysiology is characterised by type I interferon (IFN) dysregulation. This study aims to assess the efficacy, safety, and target engagement of dazukibart, a potent, selective, humanised IgG1 neutralising monoclonal antibody directed against IFNβ, in adults with moderate-to-severe dermatomyositis.
Methods: This multicentre, double-blind, randomised, placebo-controlled, phase 2 trial was conducted at 25 university-based hospitals and outpatient sites in Germany, Hungary, Poland, Spain, and the USA.
BMC Oral Health
December 2024
Dental Sciences Graduate Program. Federal University of Espirito Santo (UFES), Avenida Maruípe 1468, Maruípe, Vitória, 29040-090, ES, Brazil.
Cureus
October 2024
Family Medicine, St. Joseph's Regional Medical Center, Paterson, USA.
This is the case of chronic chromoblastomycosis (CBM) in a 61-year-old male from the Dominican Republic (DR) with extensive cutaneous eruptions over multiple areas of the body including bilateral lower extremities and the flank extending to the back. A 61-year-old male with a history of morbid obesity, chronic kidney disease stage III, and well-controlled hypertension presented to the family medicine clinic for the evaluation of chronic painful skin lesions on his legs and torso. The lesions began 19 years prior, following a flood in the Dominican Republic (DR) where he was living at the time.
View Article and Find Full Text PDFJ Cutan Med Surg
November 2024
Cancer Research Program, McGill University Health Centre Research Institute, Montreal, QC, Canada.
Allergol Select
October 2024
Center for Child and Adolescent Health, Helios Hospital Krefeld, Academic Hospital of RWTH Aachen, Krefeld.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!